- Category
- augmentation
- Made by
- Helix Biotech
- Tier
- Silver
Overview
Fidelity Suite is the perceptual-bandwidth subscription Helix Pharma sells to Elevation- and Transcendence-tier subscribers whose annual Optimize diagnostic has flagged perceptual variance. The product is administered as a slim ear-and-temple wearable with a daily neural-handshake activation, calibrated quarterly to the subscriber's perceptual-bandwidth profile. Helix's clinical literature classifies the variance as resolution sickness; the brand markets the subscription as the regimen that "restores" the bandwidth. The brand is sincere: perception, restored — compliance, continuous.
The product is also, in audit terms, the most documented monetization-of-internal-classification on Helix's books. Resolution sickness was identified by Helix engineers in 2176 as "non-critical perceptual variance within normal operating parameters" and classified as non-critical in three subsequent audits. In 2183, the same engineering organization reclassified the variance as a treatable condition and launched the Fidelity Suite at ¢14,000 per year with a 4.7% cancellation rate, achieving a target metric the Board reviews quarterly. The Suite does not restore stripped perceptual bandwidth; it temporarily reallocates 3-5% cognitive bandwidth to sensory channels, creating a new dependency rung users rarely step down from. Internal materials describe the reallocation as "fidelity discipline." The 4.7% cancellation rate has held within tolerance every year since launch.
Packaging & Appearance
The Fidelity Suite wearable is a surgical-white slim ear-and-temple band with the Helix double-helix etched in deep green into the soft-touch surface and a soft cyan reallocation halo at the neural-handshake antenna near the temple. The halo brightens at activation and dims after the daily reallocation cycle completes. The band is sized to the gloved hand of the consulting Helix clinician at the counter, where the device is paired to the subscriber's perceptual-bandwidth profile. The translucent readout displays the calibrated 3-5% reallocation curve, the metric labeled in clinical proprietary capitalization. The label carries regulatory text in three font sizes and a QR code linking to a 47-page reallocation document available only to credentialed clinicians under NDA. The wearable is engineered to be photographed at the post-reallocation moment when the subscriber is calm at affect baseline.
Ingredients
Helix Fidelity Matrix v3.0 (proprietary; full composition disclosed only to credentialed clinicians under NDA — perceptual reallocation cofactors, bandwidth modulation compounds, sensory-channel calibration profile). Neural-handshake activation (single-use daily, ingestion-grade). Compliance telemetry (passive, continuous, ninety-day retention). Annual subscription (¢14,000, calendared monthly, automatic renewal). Quarterly bandwidth reallocation curve calibration.
Unverified Intelligence
Unverified · in-world intelligence
Off-grid clinics in the outer Sprawl report a black-market variant — counterfeit Fidelity Suite hardware running unlicensed reallocation profiles. The counterfeit curve is reportedly less stable than the calibrated Helix version but routes telemetry to no insurer. Helix has filed three regulatory complaints; two were acted on. The third is pending review by a regulatory body that received a ¢2.1M infrastructure grant from Helix in 2182.
At least one Helix engineer involved in the 2176 non-critical classification is currently enrolled in the Fidelity Suite on a complimentary corporate subscription, with an enrollment date eight months before the public 2183 launch. This is either evidence of internal early access or evidence the product was ready before the classification changed. Helix has not commented.
A decompiled firmware image from a 2183-era wearable suggests the reallocation ceiling was originally calibrated at 6–8% before being adjusted down to the published 3–5% range prior to launch. No explanation for the adjustment appears in any available documentation.
Marketing
